Page last updated: 2024-09-05

tolvaptan and ADPKD

tolvaptan has been researched along with ADPKD in 167 studies

Research

Studies (167)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (1.80)	29.6817
2010's	82 (49.10)	24.3611
2020's	82 (49.10)	2.80

Authors

Authors	Studies
Cao, X; Chen, Y; Cheng, J; Fu, K; Guo, D; Hu, Y; Su, L; Sun, Y; Wang, P; Wang, Y; Wang, Z; Xu, Z; Yan, W; Yuan, H; Zhang, H	1
Cao, X; Fang, Q; Fu, K; Guo, D; He, Y; Liu, H; Su, L; Wang, J; Wang, P; Xie, Y; Xiong, X; Xu, P; Yin, L; Yuan, H; Zhang, H; Zhu, X	1
Ishibashi, Y; Kitayama, C; Uchiyama, K; Yanai, A	1
Hirama, A; Ikeda, M; Kashiwagi, T; Kawasaki, S; Sakai, Y; Shimoda, N; Yan, T	1
Schmitt, R; Wulfmeyer, VC	1
Caprara, C; Corradi, V; Gastaldon, F; Giuliani, A; Marcello, M; Marturano, D; Rigato, M; Ronco, C; Zanella, M	1
Buonanno, P; Capuano, I; Pisani, A; Riccio, E; Rizzo, M	1
Butcher, BE; Gois, PHF; Ta, MHT; Thomas, M; Van Wyk, GW	1
Bhardwaj, G; Dai, DF; Daneshgar, N; Horstmann, MM; Lan, RS; Liang, PI; O'Neill, BT; Pack, L; Penniman, CM	1
Birn, H; Capasso, G; Cornec-Le Gall, E; Devuyst, O; Gansevoort, RT; Guirchoun, P; Harris, T; Hoorn, EJ; Knoers, NVAM; Korst, U; Le Meur, Y; Mekahli, D; Messchendorp, AL; Müller, RU; Nijenhuis, T; Ong, ACM; Sayer, JA; Schaefer, F; Servais, A; Tesar, V; Torra, R; van Eerde, A; Walsh, SB	1
Akihisa, T; Kataoka, H; Makabe, S; Manabe, S; Mochizuki, T; Nitta, K; Sato, M; Tsuchiya, K; Ushio, Y; Yoshida, R	1
Hasegawa, E; Hoshino, J; Ikuma, D; Mizuno, H; Sawa, N; Sekine, A; Suwabe, T; Ubara, Y; Yamanouchi, M	1
Reiterová, J; Tesař, V	1
Cobo, M; Delgado-Mallén, P; Escamilla, B; Estupiñán, S; Fernandez, JM; Ferrer-Moure, C; Gaspari, F; Gómez, MVP; González, IH; González-Delgado, A; González-Rinne, F; Luis-Lima, S; Marco, CO; Martín, LD; Mena, NN; Ortiz, A; Perera, CC; Porrini, E; Reyes, SP; Rodriguez Pérez, JC; Rodríguez, RM; Toledo, BG; Torres, A; Zulueta, BL	1
Akihisa, T; Kataoka, H; Makabe, S; Manabe, S; Mochizuki, T; Nitta, K; Sato, M; Tsuchiya, K; Ushio, Y; Watanabe, K; Yoshida, R	1
Honda, K; Inoue, D; Inoue, R; Nangaku, M; Nishi, H	1
Bertoldi, G; Calò, LA; Carraro, G; Cirella, I; Di Vico, V; Dian, S; Ravarotto, V; Rigato, M	1
Guerra-Torres, XE	1
Aihara, M; Fujiki, H; Hattori, K; Isakari, Y; Mizuguchi, H; Nagano, K; Ohmoto, K; Takeshita, Y; Yamada, Y; Yamamoto, M; Yamamura, Y	1
Baldini Anastasio, P; Bugnotto, B; Calò, LA; Campo, D; Carraro, G; Cirella, I; di Vico, V; Rigato, M	1
Chan, T; de Zoysa, JR; van der Merwe, W	1
Ding, L; Gong, L; Jiang, W; Lu, J; Qian, X; Tang, W; Xie, F; Xu, M; Xu, W	1
Agraz-Pamplona, I; Alvarez, C; Álvarez-Mora, MI; Bastida, C; Blasco, M; Broseta, JJ; Furlano, M; Nicolau, C; Piñeiro, GJ; Poch, E; Quintana, LF; Rodríguez-Espinosa, D; Ruiz, C; Sánchez-Baya, M; Torra-Balcells, R	1
Aguiari, G; Bianchi, N; Giattino, A; Giorgi, C; Patergnani, S; Pinton, P	1
Alpers, DH; Estilo, A; Freston, JW; Hoke, ME; Hunt, CM; Lewis, JH; Li, H; Roth, SE; Torres, VE; Wang, W; Westcott-Baker, L	1
Ichihara, N; Kumamaru, H; Miyachi, Y; Miyata, H; Mori, K; Nishimura, S; Saito, R; Shimada, K; Yamamoto, H	1
Barnett, CL; Mader, G; Mladsi, D; Oberdhan, D; Purser, M; Sanon, M; Seliger, S; Watnick, T	1
Anderegg, MA; Bargagli, M; Dhayat, NA; Faller, N; Ferraro, PM; Fuster, DG; Huynh-Do, U; Vetsch, A; Vogt, B	1
Hashimoto, M; Higashiura, A; Honda, M; Iijima, H; Iwasaki, A; Kiriki, M; Nagasawa, Y; Nishimura, T; Tada, T; Yamakado, K	1
Quiroga, B; Torra, R	1
Hammond, S; Meng, X; Mosedale, M; Naisbitt, DJ	1
Cullaro, G; Park, M; Postalcioglu, M	1
Hartung, EA	1
Cadnapaphornchai, MA; Dandurand, A; Greenbaum, LA; Guay-Woodford, LM; Litwin, M; Mekahli, D; Schaefer, F; Seeman, T; Shi, L; Shoaf, SE; Sikes, K	1
Cao, X; Chen, T; Fu, K; Guo, D; Hu, H; Liu, H; Ren, Y; Su, L; Wang, P; Yuan, H; Zhang, Y; Zhao, W	1
Hogan, MC; Masyuk, TV	1
Brambilla, P; Caroli, A; Carrara, F; Caruso, M; Cugini, D; Leone, VF; Martinetti, D; Peracchi, T; Perico, N; Perna, A; Remuzzi, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trillini, M; Villa, G	1
Cadnapaphornchai, MA; Goldstein, SL; Greenbaum, LA; Guay-Woodford, LM; Liebau, MC; Litwin, M; Mekahli, D; Schaefer, F; Seeman, T	1
Torres, VE; Zhou, JX	2
de la Rosa, RE; García, AIM; García, EM; Moyano, AP; Oporto, FR; Utiel, FJB	1
Ackley, W; Dahl, NK; Park, M	1
Han, S; Kim, Y	1
Patel, SJ; Sadowski, CK	1
Brownlee, RT; Cleary, HL; Fisher, JL; George, JF; Howton, TC; Lasseigne, BN; McPherson, KC; Mrug, M; Oza, VH; Wilk, EJ; Yoder, BK	1
Cho, H; Kim, H; Kim, YC; Kim, YH; Lee, MK; Lee, YS; Min, HS; Shin, JH; Shin, TY	1
Davenport, E; Fernandes, AW; Krasa, HB; Lioudis, M; Nunna, S; Oberdhan, D; Zhou, X	1
Balcı, S; Dervisoglu, E; Eren, N; Ergul, M; Gocay Bek, SG; Guven Taymez, D; Islam, M; Kalender, B; Sarıoglu, I; Tosun, M; Uslu, H; Waldreus, N; Yıldız, N	1
Fujimaru, T; Furuichi, K; Hanaoka, K; Hattanda, F; Hayashi, H; Hidaka, S; Horie, S; Hoshino, J; Ichikawa, D; Ishikawa, E; Kai, H; Kataoka, H; Katayama, K; Kawano, H; Kimura, T; Kurashige, M; Makabe, S; Manabe, S; Mitobe, M; Miura, K; Mochizuki, T; Moriyama, T; Muto, S; Nakanishi, K; Nakatani, S; Narita, I; Nishio, S; Okada, H; Otsuka, T; Sato, M; Sekine, A; Seta, K; Shimabukuro, W; Shimada, Y; Shimazu, K; Suwabe, T; Tsuchiya, K; Uchiyama, K	1
Fenton, RA; Gansevoort, RT; Geurts, F; Hoorn, EJ; Kramers, BJ; Meijer, E; Salih, M; Xue, L; Zietse, R	1
Auber, B; Haller, H; Schmitt, R; Wulfmeyer, VC	1
Annicchiarico Petruzzelli, L; Pellegrino, AM; Pisani, A; Riccio, E	1
Bai, DH; Cai, Q; Guo, XY; Lu, AM; Sheng, HZ; Wang, BK; Wang, XR; Xie, X; Yan, K	1
Calvaruso, L; Chicca, S; Galliani, M; Iorio, F; Moscaritolo, E; Paone, A; Vitaliano, E	1
Chen, M; Gu, J; Hu, S; Li, D; Tan, X; Zhang, X	1
Howell, BA; Pellegrini, L; Shoda, LKM; Woodhead, JL	1
Anderson, CL	1
Gansevoort, RT	1
Agharazii, M; Asselin-Thompstone, L; Côté, G; Desmeules, S; Lacroix, C; Mac-Way, F; René de Cotret, P	1
Bange, H; Dijkstra, KL; Kanhai, AA; Leonhard, WN; Peters, DJM; Price, LS; Verburg, L	1
Chakraborty, R; DeCoy, ME; Kline, T; Raina, R	1
Agraz-Pamplona, I; Bury-Macias, RP; Larrosa-Garcia, M; Montoro-Ronsano, JB; Serón-Micas, D	1
Hoorn, EJ; Zietse, R	1
Amicone, M; Angelucci, V; Pisani, A; Riccio, E	1
Gordon, CE; Perrone, RD	1
Gansevoort, RT; Meijer, E	1
Beaudoin, JJ; Brock, WJ; Brouwer, KLR; Watkins, PB	1
Ando, F; Chiga, M; Fujimaru, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Kawada, M; Kikuchi, H; Mandai, S; Mizuno, H; Mori, T; Sawa, N; Sekine, A; Sohara, E; Suwabe, T; Takaichi, K; Ubara, Y; Uchida, S; Yamanouchi, M	1
Assimos, DG	1
Cianci, R; Cipolloni, E; Falco, F; Gasperini, ML; Gigante, A; Giovannetti, A; Lai, S; Mangiulli, M; Mastroluca, D; Mazzaferro, S; Mitterhofer, AP; Muscaritoli, M; Napoleoni, L; Perrotta, AM	1
Gibson, A; Hammond, S; Jaruthamsophon, K; Mosedale, M; Naisbitt, DJ; Roth, S	1
Fukami, K; Hazama, T; Ito, S; Kaida, Y; Koda, Y; Kodama, G; Kurokawa, Y; Moriyama, T; Nakamura, N; Nakayama, Y; Ota, K; Shibata, R; Soejima, M; Takamiya, Y; Ueda, U; Yano, J; Yokota, Y	1
Abe, H; Doi, T; Inoue, T; Kawahara, K; Kishi, S; Minakuchi, J; Miya, K; Murakami, T; Nagai, K; Nishimura, K; Ono, H; Shibata, E; Shima, H; Tamaki, M; Tashiro, M; Ueta, S	1
Fukuhara, H; Furukawa, T; Higashihara, E; Horie, S; Kaname, S; Kawano, H; Muto, S; Taguchi, S; Tambo, M; Yamaguchi, T; Yokoyama, K; Yoshioka, T	1
Collard, L; Dachy, A; Ghuysen, MS; Jouret, F; Krzesinski, JM; Mekahli, D; Seghaye, MC	1
Chapman, AB; Devuyst, O; Estilo, A; Gansevoort, RT; Hoke, ME; Lee, J; Perrone, RD; Sergeyeva, O; Torres, VE	1
Dahl, NK; Patel, DM	1
Horie, S; Ibuki, T; Kawano, H; Muto, S; Nakajima, K; Okada, T; Shibasaki, Y	1
Cuka, E; Joli, G; Manunta, P; Sciarrone Alibrandi, TM; Vespa, M	1
Chebib, FT; Torres, VE	1
Amicone, M; Buonanno, P; Capuano, I; Pisani, A; Riccio, E	1
Horie, S; Ibuki, T; Muto, S; Okada, T; Shibasaki, Y	1
Goggolidou, P; Malik, SA; Modarage, K; Richards, T	1
Fenton, RA; Olesen, ETB	1
Endo, K; Hatano, T	1
Blais, JD; Chapman, AB; Czerwiec, FS; Dandurand, A; Devuyst, O; Gansevoort, RT; Ouyang, J; Perrone, RD; Torres, VE	1
De Rechter, S; Janssens, P; Liebau, MC; Mekahli, D; Weydert, C; Wissing, KM	1
Carroll, KJ; Koch, G; Li, J; Ouyang, J	1
Torres, VE; van Gastel, MDA	1
Al Therwani, S; Bech, JN; Malmberg, MES; Pedersen, EB; Rosenbaek, JB	1
Blais, JD; Chapman, AB; Cornec-Le Gall, E; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Harris, PC; Heyer, CM; Irazabal, MV; Le Meur, Y; Ouyang, J; Perrone, RD; Senum, SR; Torres, VE	1
Hamano, T; Isaka, Y; Iwatani, H; Kimura, Y; Minami, S; Mizui, M	1
Ingelfinger, JR	1
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Koch, G; McQuade, RD; Ouyang, J; Perrone, RD; Sergeyeva, O; Torres, VE	1
Andreisek, G; Kistler, AD	1
Czerwiec, FS; Gansevoort, RT; Torres, VE	1
Le Meur, Y; Wyatt, CM	1
De Tymowski, C; Legrand, M	1
Pazmiño, PA	1
Bennett Wilton, H; Cabrera, MV; McEwan, P; O'Reilly, K; Ong, ACM; Robinson, P; Sandford, R; Scolari, F; Walz, G; Ørskov, B	1
Bitterman, S; Blount, KL; Dahl, NK; Dai, F; Droher, M; Herzog, EL; Karihaloo, A; Lee, Y; Moeckel, G; Scher, JK; Thompson, S	1
Aoyama, Y; Kataoka, H; Makabe, S; Mitobe, M; Mochizuki, T; Nitta, K; Tsuchiya, K	1
Abraham, AG; Blum, M; Galletti, F; Girardat-Rotar, L; Puhan, MA; Serra, AL; Ziegler, S	1
Mustafa, RA; Yu, ASL	1
Higashihara, E; Miyazaki, I; Nutahara, K; Okegawa, T; Yamaguchi, T	1
Altobelli, C; Cerutti, R; Dallera, N; Esposito, C; La Milia, V; Magistroni, R; Manunta, P; Piscopo, G	1
De Smedt, H; Decuypere, JP; Janssens, P; Mekahli, D; Vennekens, R; Weydert, C	1
Chapman, AB; Chebib, FT; Dahl, NK; Harris, PC; Mrug, M; Mustafa, RA; Perrone, RD; Rastogi, A; Torres, VE; Watnick, T; Yu, ASL	1
Blasco, M; Molina, A; Poch, E; Quintana, L; Rodas, L	1
Torres, VE	3
Gross, P; Paliege, A; Schirutschke, H	1
Ars, E; Ayasreh, N; Ballarín, J; Bullich, G; Furlano, M; Loscos, I; Martí, T; Rius, A; Roca, L; Torra, R	1
Beaudoin, JJ; Bezençon, J; Brock, WJ; Brouwer, KLR; Cao, Y; Mizuno, K; Roth, SE	1
Boertien, WE; Gansevoort, RT; Kramers, BJ; Meijer, E; van Gastel, MDA	1
Lanke, S; Shoaf, SE	1
Blair, HA	1
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Higashihara, E; Lee, J; Ouyang, J; Perrone, RD; Stade, K; Torres, VE; van Gastel, MDA	1
Emoto, M; Fujimoto, K; Inaba, M; Ishimura, E; Machiba, Y; Mori, K; Nakatani, A; Nakatani, S; Okute, Y; Tsuda, A; Uedono, H	1
Bennett, H; Hamilton, K; McEwan, P; O'Reilly, K	1
Gaur, P; Gedroyc, W; Hill, P	1
Bockenhauer, D; Cadnapaphornchai, MA; Dandurand, A; Emma, F; Gilbert, RD; Mekahli, D; Schaefer, F; Shi, L; Shoaf, SE; Sikes, K	1
Fernández Fresnedo, G; López Del Moral Cuesta, C; Martín Penagos, L	1
Bankir, L; Bichet, DG	1
Carriazo, S; Cordido, A; García-González, MA; Ortiz, A; Perez-Gomez, MV; Sanchez-Niño, MD; Sanz, AB	1
Bakker, SJ; Boertien, WE; Czerwiec, FS; de Jong, PE; Gansevoort, RT; Krasa, HB; Meijer, E; Oberdhan, D; Shoaf, SE; Struck, J	1
Chertow, GM; Erickson, KF; Goldhaber-Fiebert, JD	1
Powe, NR; Tuot, DS	1
Torra, R	1
Benzing, T; Rinschen, MM; Schermer, B	1
Mei, C; Wüthrich, RP	2
Baur, BP; Meaney, CJ	1
Harris, PC; Hommerding, CJ; Hopp, K; Torres, VE; Wang, X; Ye, H	1
Cornec-Le Gall, E; Le Meur, Y	1
Boertien, WE; Czerwiec, FS; de Jong, PE; Engels, GE; Gansevoort, RT; Kappert, P; Krasa, HB; Meijer, E; Oberdhan, D; Ouyang, J; Renken, RJ; Struck, J; ter Horst, GJ; van der Jagt, EJ; van Oeveren, W	1
Higashihara, E; Horie, S; Kawano, H; Matsuzaki, T; Muto, S; Narita, I; Ouyang, J; Torres, VE; Ubara, Y	1
Horie, S	1
Buemi, M; Cernaro, V; Pellicanò, V; Santoro, D; Trifirò, G; Visconti, L	1
Alpers, DH; Blais, JD; Czerwiec, FS; Kaplowitz, N; Krasa, H; Lewis, JH; Ouyang, J; Smotzer, DM; Torres, VE; Watkins, PB; Zimmer, CA	1
Boertien, WE; Engels, GE; Gansevoort, RT; Harskamp, LR; Meijer, E; van Goor, H; van Oeveren, W	1
Schumacher, B	1
Blair, HA; Keating, GM	1
Brock, WJ; Brouwer, KL; Brouwer, KR; Freeman, KM; Lu, Y; Pan, M; Slizgi, JR; St Claire, RL	1
Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Krasa, HB; Meijer, E; Ouyang, J; Perrone, RD; Torres, VE	1
Simms, RJ	1
Arici, M; Benzing, T; Birn, H; Capasso, G; Covic, A; Devuyst, O; Drechsler, C; Eckardt, KU; Emma, F; Gansevoort, RT; Knebelmann, B; Le Meur, Y; Massy, ZA; Ong, AC; Ortiz, A; Schaefer, F; Torra, R; Van Biesen, W; Vanholder, R; Więcek, A; Zoccali, C	1
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Ouyang, J; Perrone, RD; Torres, VE	1
Blais, J; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Krasa, H; Ouyang, J; Perrone, RD; Torres, VE; Zhou, W	1
Bae, KT; Casteleijn, NF; Higashihara, E; Kappert, P; Leliveld, AM; Meijer, E; Messchendorp, AL; Torres, V	1
Banach, M; Bartnicki, P; Franczyk, B; Gluba-Brzózka, A; Rysz, J	1
Caprara, C; Corradi, V; Ferrari, F; Gastaldon, F; Giuliani, A; Martino, F; Ronco, C	1
Blais, JD; Casteleijn, NF; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Higashihara, E; Leliveld, AM; Ouyang, J; Perrone, RD; Torres, VE	1
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Higashihara, E; Ouyang, J; Perrone, RD; Torres, VE; Zhou, W	1
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Ouyang, J; Perrone, RD; Sergeyeva, O; Torres, VE	1
Evans, H; Gilbert, RD; Griffiths, M; Haq, MR; Nagra, A; Olalekan, K	1
Bae, KT; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Krasa, HB; Meijer, E; Ouyang, JJ; Perrone, RD; Torres, VE	1
Czerwiec, FS; Glockner, J; Hogan, MC; Irazabal, MV; King, BF; Krasa, HB; Ofstie, TG; Ouyang, J; Torres, VE	1
Fujiki, H; Nivens, E; Pinto, CS; Reif, GA; Wallace, DP; Yamaguchi, T	1
Bae, K; Chapman, AB; Czerwiec, FS; Grantham, JJ; Higashihara, E; Horie, S; Krasa, HB; Nutahara, K; Ouyang, J; Torres, VE; Watnick, TJ	1
Burtey, S	1
Chang, MY; Ong, AC	1
Steinman, TI	1
Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Krasa, HB; Ouyang, J; Perrone, RD; Torres, VE	1
Bennett, WM	1
Edelstein, CL	1

Reviews

40 review(s) available for tolvaptan and ADPKD

Article	Year
[What is evidence-based in the treatment of autosomal dominant polycystic kidney disease?] Der Internist, 2021, Volume: 62, Issue:12 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2021
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature. Clinical nephrology, 2022, Volume: 97, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Glomerular Filtration Rate; Humans; Octreotide; Polycystic Kidney, Autosomal Dominant; Somatostatin; Tolvaptan	2022
Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment. International journal of molecular sciences, 2022, Mar-19, Volume: 23, Issue:6 Topics: Animals; Apoptosis; Cysts; Humans; Phosphatidylinositol 3-Kinases; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2022
Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis. International urology and nephrology, 2023, Volume: 55, Issue:3 Topics: Abdominal Pain; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Hematuria; Humans; Hypertension; Polycystic Kidney, Autosomal Dominant; Polyuria; Tolvaptan	2023
Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression. Nutrients, 2022, Nov-03, Volume: 14, Issue:21 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan	2022
Drug repurposing in autosomal dominant polycystic kidney disease. Kidney international, 2023, Volume: 103, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Drug Repositioning; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. Advances in kidney disease and health, 2023, Volume: 30, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon. Advances in kidney disease and health, 2023, Volume: 30, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Renal Insufficiency; Tolvaptan; United States; Vasopressins	2023
Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease. The Korean journal of internal medicine, 2023, Volume: 38, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Quality of Life; Tolvaptan	2023
Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis. Combinatorial chemistry & high throughput screening, 2020, Volume: 23, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Tolvaptan	2020
[ADPKD treatment: Tolvaptan and Octreotide]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2019, Dec-09, Volume: 36, Issue:6 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Octreotide; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021, Volume: 78, Issue:2 Topics: Age Factors; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Magnetic Resonance Imaging; Organ Size; Polycystic Kidney, Autosomal Dominant; Risk Assessment; Tolvaptan; Tomography, X-Ray Computed; Ultrasonography	2021
Therapeutic advances in ADPKD: the future awaits. Journal of nephrology, 2022, Volume: 35, Issue:2 Topics: Animals; Apoptosis; Calcium; Humans; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan; TRPP Cation Channels	2022
The cellular pathways and potential therapeutics of Polycystic Kidney Disease. Biochemical Society transactions, 2021, 06-30, Volume: 49, Issue:3 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Genetic Predisposition to Disease; Humans; Kidney; Mutation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Signal Transduction; Tolvaptan	2021
Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases. Nature reviews. Nephrology, 2021, Volume: 17, Issue:11 Topics: A Kinase Anchor Proteins; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Cell Membrane; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; ErbB Receptors; Fluconazole; Humans; Kidney Tubules, Collecting; Polycystic Kidney, Autosomal Dominant; Protein Transport; Proto-Oncogene Proteins pp60(c-src); Receptors, Vasopressin; Signal Transduction; Tolvaptan; Water; Water-Electrolyte Balance; Wnt-5a Protein	2021
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children? Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:3 Topics: Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Child; Cyclic AMP; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Signal Transduction; Tolvaptan; Vasopressins	2018
Polycystic Kidney Disease and the Vasopressin Pathway. Annals of nutrition & metabolism, 2017, Volume: 70 Suppl 1 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Vasopressins	2017
Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging. Praxis, 2018, Volume: 107, Issue:3 Topics: Adolescent; Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diagnostic Imaging; Disease Progression; Drug Approval; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Kidney Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Polycystic Kidney, Autosomal Dominant; Prognosis; Receptors, Vasopressin; Tolvaptan; Tomography, X-Ray Computed; Ultrasonography; Young Adult	2018
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. Journal of the American Society of Nephrology : JASN, 2018, Volume: 29, Issue:10 Topics: Algorithms; Antidiuretic Hormone Receptor Antagonists; Clinical Protocols; Dehydration; Disease Progression; Diuresis; Female; Glomerular Filtration Rate; Humans; Liver; Magnetic Resonance Imaging; Male; Patient Selection; Polycystic Kidney, Autosomal Dominant; Time Factors; Tolvaptan; Treatment Outcome	2018
An update on tolvaptan for autosomal dominant polycystic kidney disease. Drugs of today (Barcelona, Spain : 1998), 2018, Volume: 54, Issue:9 Topics: Antidiuretic Hormone Receptor Antagonists; Clinical Trials as Topic; Drug Interactions; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2018
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs, 2019, Volume: 79, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Dose-Response Relationship, Drug; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Tolvaptan; Treatment Outcome	2019
ADPKD-what the radiologist should know. The British journal of radiology, 2019, Volume: 92, Issue:1098 Topics: Antidiuretic Hormone Receptor Antagonists; Carcinoma, Renal Cell; Cysts; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Humans; Kidney Calculi; Kidney Neoplasms; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
Dietary Care for ADPKD Patients: Current Status and Future Directions. Nutrients, 2019, Jul-12, Volume: 11, Issue:7 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
[Treatment of autosomal dominant polycystic kidney disease]. Medicina clinica, 2014, Jan-21, Volume: 142, Issue:2 Topics: Adult; Aged; Animals; Benzazepines; Disease Models, Animal; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Kidney; Male; Middle Aged; Models, Biological; Molecular Targeted Therapy; Organ Size; Polycystic Kidney, Autosomal Dominant; Renal Replacement Therapy; Renin-Angiotensin System; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases; TRPP Cation Channels; Young Adult	2014
Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again. Journal of the American Society of Nephrology : JASN, 2014, Volume: 25, Issue:6 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney Tubules, Collecting; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Signal Transduction; Tolvaptan	2014
Pharmacological management of polycystic kidney disease. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:8 Topics: Animals; Benzazepines; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Protein Kinase Inhibitors; Tolvaptan; Treatment Outcome	2014
Review of tolvaptan for autosomal dominant polycystic kidney disease. Pharmacotherapy, 2014, Volume: 34, Issue:6 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Dose-Response Relationship, Drug; Drug Interactions; Half-Life; Humans; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan	2014
[Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?]. Nephrologie & therapeutique, 2014, Volume: 10, Issue:6 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Management; Disease Models, Animal; Drugs, Investigational; Epithelial Cells; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Mice; Models, Biological; Multicenter Studies as Topic; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Renin-Angiotensin System; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases	2014
[New strategy for the treatment of autosomal dominant polycystic kidney disease]. Nihon Jinzo Gakkai shi, 2015, Volume: 57, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Clinical Trials as Topic; Drug Discovery; Humans; Molecular Targeted Therapy; Mutation; Polycystic Kidney, Autosomal Dominant; Practice Guidelines as Topic; Tolvaptan; TRPP Cation Channels	2015
An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease. Expert opinion on investigational drugs, 2015, Volume: 24, Issue:9 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Drug Design; Drugs, Investigational; Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2015
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs, 2015, Volume: 75, Issue:15 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan	2015
Autosomal dominant polycystic kidney disease. BMJ (Clinical research ed.), 2016, Feb-11, Volume: 352 Topics: Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Humans; Hypertension; Polycystic Kidney, Autosomal Dominant; Risk Factors; Tolvaptan	2016
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016, Volume: 31, Issue:3 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Europe; Humans; Hyponatremia; Polycystic Kidney, Autosomal Dominant; Societies, Medical; Tolvaptan	2016
Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:15 Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Disease Progression; Drug Therapy, Combination; Humans; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan; TOR Serine-Threonine Kinases	2016
Predictors of rapid disease progression in autosomal dominant polycystic kidney disease. Minerva medica, 2017, Volume: 108, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Clinical Trials as Topic; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Organ Size; Polycystic Kidney, Autosomal Dominant; Renin-Angiotensin System; Retrospective Studies; Tolvaptan; TRPP Cation Channels	2017
Treatment strategies and clinical trial design in ADPKD. Advances in chronic kidney disease, 2010, Volume: 17, Issue:2 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Benzazepines; Clinical Trials as Topic; Genetic Therapy; Humans; Octreotide; Polycystic Kidney, Autosomal Dominant; Sirolimus; Tolvaptan	2010
[Slow the pace of renal failure in autosomal dominant polycystic kidney disease: hopes and disappointments]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:11 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chromosomes, Human, Pair 16; Clinical Trials as Topic; Comorbidity; Cyclic AMP; DNA Mutational Analysis; Drugs, Investigational; Genetic Carrier Screening; Histone Deacetylases; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Metformin; Mice; Polycystic Kidney, Autosomal Dominant; Prognosis; Rats; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases; TRPP Cation Channels; Valproic Acid	2011
Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron. Clinical practice, 2012, Volume: 120, Issue:1 Topics: Aniline Compounds; Antihypertensive Agents; Benzazepines; Clinical Trials as Topic; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Depression, Chemical; Disease Management; Double-Blind Method; Drugs, Investigational; Forecasting; Histone Deacetylase Inhibitors; Humans; Multicenter Studies as Topic; Nitriles; Polycystic Kidney, Autosomal Dominant; Purines; Quinolines; Randomized Controlled Trials as Topic; Roscovitine; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases; Translational Research, Biomedical	2012
Polycystic kidney disease: a 2011 update. Current opinion in nephrology and hypertension, 2012, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtration Rate; Humans; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Indazoles; Kidney; Metformin; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Sirolimus; Sodium; Tolvaptan	2012
Role of vasopressin antagonists. Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:4 Topics: Adolescent; Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Fluids; Cell Proliferation; Drug Evaluation, Preclinical; Hormone Antagonists; Humans; Kidney; Male; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan; Treatment Outcome	2008

Trials

31 trial(s) available for tolvaptan and ADPKD

Article	Year
The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial. Scientific reports, 2021, 09-03, Volume: 11, Issue:1 Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Kidney; Male; Middle Aged; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Quality of Life; Sodium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome; Trichlormethiazide	2021
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease Inte Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022, 04-25, Volume: 37, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Female; Humans; Kidney; Male; Patient Selection; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2022
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial. Clinical journal of the American Society of Nephrology : CJASN, 2023, 01-01, Volume: 18, Issue:1 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Child; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Quality of Life; Tolvaptan	2023
Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial. Clinical journal of the American Society of Nephrology : CJASN, 2023, 02-01, Volume: 18, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Cross-Over Studies; Humans; Kidney; Octreotide; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Treatment Outcome	2023
Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression. Pediatric research, 2021, Volume: 89, Issue:4 Topics: Adolescent; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney; Liver; Male; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Risk; Tolvaptan; Treatment Outcome; Young Adult	2021
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clinical journal of the American Society of Nephrology : CJASN, 2020, 12-31, Volume: 16, Issue:1 Topics: Adult; Alanine Transaminase; Antidiuretic Hormone Receptor Antagonists; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Time Factors; Tolvaptan	2020
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease. Clinical and experimental nephrology, 2021, Volume: 25, Issue:5 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Body Height; Body Mass Index; Body Weight; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Organ Size; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Sex Factors; Tolvaptan; Urine	2021
Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan. Clinical and experimental nephrology, 2021, Volume: 25, Issue:9 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Japan; Kidney; Male; Middle Aged; Organ Size; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2021
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018, 03-01, Volume: 33, Issue:3 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Glomerular Filtration Rate; Humans; Male; Polycystic Kidney, Autosomal Dominant; Prognosis; Time-to-Treatment; Tolvaptan	2018
Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case study. Pharmaceutical statistics, 2017, Volume: 16, Issue:4 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2017
Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. BMC nephrology, 2017, Aug-15, Volume: 18, Issue:1 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Cross-Over Studies; Double-Blind Method; Epithelial Sodium Channels; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nitric Oxide; Polycystic Kidney, Autosomal Dominant; Sodium; Tolvaptan; Treatment Outcome; Water; Young Adult	2017
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018, 04-01, Volume: 33, Issue:4 Topics: Adolescent; Adult; Age Factors; Antidiuretic Hormone Receptor Antagonists; Clinical Trials as Topic; Disease Progression; Female; Gene Rearrangement; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Predictive Value of Tests; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Severity of Illness Index; Tolvaptan; TRPP Cation Channels; Young Adult	2018
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. The New England journal of medicine, 2017, 11-16, Volume: 377, Issue:20 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Bilirubin; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Young Adult	2017
A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC nephrology, 2018, 02-13, Volume: 19, Issue:1 Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Models, Theoretical; Polycystic Kidney, Autosomal Dominant; Predictive Value of Tests; Tolvaptan; Treatment Outcome	2018
Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019, Volume: 73, Issue:3 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Polyuria; Prospective Studies; Tolvaptan	2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney international, 2019, Volume: 96, Issue:1 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Biomarkers; Disease Progression; Female; Glomerular Filtration Rate; Glycopeptides; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Tolvaptan; Treatment Outcome; Young Adult	2019
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC nephrology, 2019, 04-23, Volume: 20, Issue:1 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Disease Management; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Polycystic Kidney, Autosomal Dominant; Proof of Concept Study; Reproducibility of Results; Time; Tolvaptan	2019
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. European journal of pediatrics, 2019, Volume: 178, Issue:7 Topics: Adolescent; Antidiuretic Hormone Receptor Antagonists; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Double-Blind Method; Female; Humans; Male; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Tolvaptan	2019
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney international, 2013, Volume: 84, Issue:6 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Female; Glomerular Filtration Rate; Hemodynamics; Hormone Antagonists; Humans; Kidney; Male; Middle Aged; Netherlands; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Renal Insufficiency, Chronic; Renal Plasma Flow, Effective; Time Factors; Tolvaptan; Treatment Outcome	2013
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clinical and experimental nephrology, 2015, Volume: 19, Issue:5 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Disease Progression; Endpoint Determination; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Japan; Kidney; Liver Function Tests; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Young Adult	2015
[Cystic kidneys can now be treated]. MMW Fortschritte der Medizin, 2015, Sep-10, Volume: 157, Issue:15 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cohort Studies; Disease Progression; Double-Blind Method; Drug Approval; Germany; Humans; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Tolvaptan	2015
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016, Volume: 31, Issue:11 Topics: Aged; Albuminuria; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Tolvaptan; Treatment Outcome	2016
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clinical journal of the American Society of Nephrology : CJASN, 2016, 05-06, Volume: 11, Issue:5 Topics: Adult; Albuminuria; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hypernatremia; Hypertension; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Pain; Polycystic Kidney, Autosomal Dominant; Severity of Illness Index; Tolvaptan	2016
Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. Clinical and experimental nephrology, 2017, Volume: 21, Issue:3 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Netherlands; Polycystic Kidney, Autosomal Dominant; Polyuria; Receptors, Vasopressin; Risk Factors; Time Factors; Tolvaptan; Treatment Outcome; Ureter; Urodynamics	2017
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:2 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Incidence; Kidney Diseases; Male; Pain; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Single-Blind Method; Time Factors; Tolvaptan	2017
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology : JASN, 2017, Volume: 28, Issue:5 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Treatment Outcome; Young Adult	2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. American journal of nephrology, 2017, Volume: 45, Issue:3 Topics: Adolescent; Adult; Aged; Benzazepines; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Patient Safety; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Renal Insufficiency, Chronic; Research Design; Tolvaptan; Treatment Outcome; Young Adult	2017
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 57, Issue:5 Topics: Adolescent; Adult; Albuminuria; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Management; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Receptors, Vasopressin; Tolvaptan; Treatment Outcome; Young Adult	2011
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney international, 2011, Volume: 80, Issue:3 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Contrast Media; Creatinine; Diuresis; Female; Glomerular Filtration Rate; Hormone Antagonists; Humans; Iothalamic Acid; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Minnesota; Organ Size; p-Aminohippuric Acid; Polycystic Kidney, Autosomal Dominant; Potassium; Receptors, Vasopressin; Renal Circulation; Time Factors; Tolvaptan; Treatment Outcome; Uric Acid	2011
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:10 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Female; Glomerular Filtration Rate; Hormone Antagonists; Humans; Japan; Kidney; Male; Middle Aged; North America; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Time Factors; Tolvaptan; Treatment Outcome; Young Adult	2011
Tolvaptan in patients with autosomal dominant polycystic kidney disease. The New England journal of medicine, 2012, Dec-20, Volume: 367, Issue:25 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Organ Size; Polycystic Kidney, Autosomal Dominant; Sodium; Tolvaptan; Young Adult	2012

Other Studies

96 other study(ies) available for tolvaptan and ADPKD

Article	Year
Long Residence Time at the Vasopressin V Journal of medicinal chemistry, 2022, 06-09, Volume: 65, Issue:11 Topics: Antidiuretic Hormone Receptor Antagonists; Drug Design; Humans; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin	2022
Benzodiazepine Derivatives as Potent Vasopressin V Journal of medicinal chemistry, 2022, 07-14, Volume: 65, Issue:13 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzodiazepines; Cyclic AMP; Cysts; Humans; Kidney; Mice; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Vasopressins	2022
Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2022, Jun-28, Volume: 89, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Clinical Trials, Phase III as Topic; Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Retrospective Studies; Tolvaptan; Treatment Outcome	2022
[Slowing progression of chronic kidney disease in polycistic kidney disease patients with tolvaptan: from guidelines to clinical practice]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2021, Oct-26, Volume: 38, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Humans; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan	2021
Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset. BMC nephrology, 2021, 12-02, Volume: 22, Issue:1 Topics: Adult; Aged; Data Analysis; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Retrospective Studies; Tolvaptan; Young Adult	2021
Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations. Kidney international, 2022, Volume: 101, Issue:5 Topics: Animals; Animals, Newborn; Female; Humans; Male; Mice; Mutation; Oligopeptides; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Pregnancy; Tolvaptan	2022
Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease. Clinical and experimental nephrology, 2022, Volume: 26, Issue:6 Topics: Antidiuretic Hormone Receptor Antagonists; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Retrospective Studies; Tolvaptan	2022
Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use. PloS one, 2022, Volume: 17, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Case-Control Studies; Cysts; Female; Humans; Kidney; Liver; Liver Diseases; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Prognosis; Retrospective Studies; Tolvaptan	2022
Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method. Journal of nephrology, 2022, Volume: 35, Issue:8 Topics: Adult; Creatinine; Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan	2022
Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2021, 07-29, Volume: 2, Issue:7 Topics: Antidiuretic Hormone Receptor Antagonists; Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Prognosis; Tolvaptan	2021
Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2020, 08-27, Volume: 1, Issue:8 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Humans; Hyponatremia; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
[Reduced oxidative stress in ADPKD patients treated with tolvaptan]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2022, Apr-21, Volume: 39, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Female; Humans; Kidney; Male; Oxidative Stress; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2022
A Case Report of Tuberous Sclerosis and Autosomal Dominant Polycystic Kidney Disease in the Era of Tolvaptan. Current reviews in clinical and experimental pharmacology, 2023, Volume: 18, Issue:3 Topics: Humans; Pedigree; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein	2023
[Tolvaptan, a vasopressin V Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2022, Volume: 157, Issue:4 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cyclic AMP; Cysts; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Vasopressins	2022
[Tolvaptan in ADPKD patients at the University of Padova Nephrology Unit: impact on quality of life, efficacy and safety]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2022, Jun-20, Volume: 39, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Nephrology; Polycystic Kidney, Autosomal Dominant; Quality of Life; Tolvaptan	2022
Delay in funding of tolvaptan for polycystic kidney disease in Aotearoa New Zealand. The New Zealand medical journal, 2022, 08-05, Volume: 135, Issue:1559 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Kidney Failure, Chronic; Native Hawaiian or Other Pacific Islander; New Zealand; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2022
Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment. Nephron, 2023, Volume: 147, Issue:3-4 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines. Biology of the cell, 2023, Volume: 115, Issue:1 Topics: Animals; Apoptosis; Cell Line; Cell Proliferation; Polycystic Kidney, Autosomal Dominant; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases; TRPP Cation Channels	2023
Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2023, Volume: 81, Issue:3 Topics: Alanine Transaminase; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chemical and Drug Induced Liver Injury; Humans; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Retrospective Studies; Tolvaptan	2023
Persistence of tolvaptan medication for autosomal dominant polycystic kidney disease: A retrospective cohort study using Shizuoka Kokuho Database. Medicine, 2022, Oct-07, Volume: 101, Issue:40 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cohort Studies; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2022
A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC nephrology, 2022, 10-18, Volume: 23, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Time Factors; Tolvaptan	2022
Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, Jun-30, Volume: 38, Issue:7 Topics: Antidiuretic Hormone Receptor Antagonists; Bone Density; Humans; Magnesium; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Tolvaptan	2023
Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease. Journal of medical ultrasonics (2001), 2023, Volume: 50, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Ultrasonography	2023
Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan. Toxicology letters, 2023, Jan-15, Volume: 373 Topics: Antidiuretic Hormone Receptor Antagonists; Clone Cells; Humans; Polycystic Kidney, Autosomal Dominant; T-Lymphocytes; Tolvaptan	2023
Much Ado About Something: The Clinical Pattern of Tolvaptan-Associated Liver Injury in Participants With ADPKD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2023, Volume: 81, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Liver; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When? Clinical journal of the American Society of Nephrology : CJASN, 2023, 01-01, Volume: 18, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Child; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Structure-Affinity and Structure-Kinetic Relationship Studies of Benzodiazepine Derivatives for the Development of Efficacious Vasopressin V Journal of medicinal chemistry, 2023, 03-09, Volume: 66, Issue:5 Topics: Anti-Anxiety Agents; Anticonvulsants; Antidiuretic Hormone Receptor Antagonists; Benzodiazepines; Humans; Hypnotics and Sedatives; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan; Vasopressins	2023
Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment? Clinical journal of the American Society of Nephrology : CJASN, 2023, 02-01, Volume: 18, Issue:2 Topics: Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Receptors, Somatostatin; Receptors, Vasopressin; Tolvaptan	2023
Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease. BMC nephrology, 2023, 02-13, Volume: 24, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Child; Cysts; Humans; Infant, Newborn; Kidney; Longitudinal Studies; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive; Tolvaptan	2023
Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan. International urology and nephrology, 2023, Volume: 55, Issue:10 Topics: Antidiuretic Hormone Receptor Antagonists; Body Weight; Creatinine; Glomerular Filtration Rate; Humans; Kidney; Male; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
An update on treatments for autosomal dominant polycystic kidney disease. JAAPA : official journal of the American Academy of Physician Assistants, 2023, 06-01, Volume: 36, Issue:6 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion. Molecular medicine (Cambridge, Mass.), 2023, 05-22, Volume: 29, Issue:1 Topics: Animals; Drug Repositioning; Gene Expression; Humans; Kidney; Mice; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan; TRPP Cation Channels	2023
Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease. Investigative and clinical urology, 2023, Volume: 64, Issue:3 Topics: Artificial Intelligence; Disease Progression; Feasibility Studies; Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC nephrology, 2023, 06-22, Volume: 24, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Thirst intensity survey in ADPKD patients. Clinical and experimental nephrology, 2023, Volume: 27, Issue:10 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Thirst; Tolvaptan	2023
Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease. Clinical and experimental nephrology, 2023, Volume: 27, Issue:10 Topics: Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Humans; Japan; Polycystic Kidney, Autosomal Dominant; Registries; Tolvaptan	2023
Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clinical journal of the American Society of Nephrology : CJASN, 2023, 11-01, Volume: 18, Issue:11 Topics: Antidiuretic Hormone Receptor Antagonists; Dinoprostone; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Kidney; Male; Osmoregulation; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Renal Insufficiency; Tolvaptan	2023
Comparison of Different Selection Strategies for Tolvaptan Eligibility among Autosomal Dominant Polycystic Kidney Disease Patients. American journal of nephrology, 2019, Volume: 50, Issue:4 Topics: Adult; Aged; Algorithms; Disease Progression; Female; Genotype; Germany; Glomerular Filtration Rate; Humans; Kidney Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Nephrology; Patient Selection; Polycystic Kidney, Autosomal Dominant; Retrospective Studies; Tolvaptan; Tomography, X-Ray Computed; Young Adult	2019
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. BMC nephrology, 2019, 11-21, Volume: 20, Issue:1 Topics: Adult; Alanine Transaminase; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antidiuretic Hormone Receptor Antagonists; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
[Research progress in autosomal dominant polycystic kidney disease]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2019, Oct-28, Volume: 44, Issue:10 Topics: Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling. Pharmaceutical research, 2020, Jan-06, Volume: 37, Issue:2 Topics: Benzamides; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Theoretical; Polycystic Kidney, Autosomal Dominant; Pyrroles; Tolvaptan	2020
Doubts about the efficacy of tolvaptan for polycystic kidney disease. Clinical nephrology, 2020, Volume: 93, Issue:6 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Reply to Dr. Anderson's letter. Clinical nephrology, 2020, Volume: 93, Issue:6 Topics: Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention. International urology and nephrology, 2020, Volume: 52, Issue:2 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Dietary Proteins; Directive Counseling; Diuresis; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Renal Elimination; Retrospective Studies; Sodium; Sodium, Dietary; Tolvaptan; Urea; Urine	2020
Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective. Scientific reports, 2020, 02-03, Volume: 10, Issue:1 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cell Culture Techniques; Combined Modality Therapy; Cysts; Disease Progression; Humans; Kidney; Male; Mice; Pioglitazone; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Rats; Rats, Wistar; Tolvaptan	2020
Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD). European journal of clinical pharmacology, 2020, Volume: 76, Issue:10 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Creatine Kinase; Humans; Male; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
ADPKD, Tolvaptan, and Nephrolithiasis Risk. Clinical journal of the American Society of Nephrology : CJASN, 2020, 07-01, Volume: 15, Issue:7 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Kidney Calculi; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
[Tolvaptan in ADPKD: a turning point or an unsustainable therapy? One year of "real life" experience]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2020, Jun-10, Volume: 37, Issue:3 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Feasibility Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Medication Adherence; Middle Aged; Patient Satisfaction; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Quality of Life; Time Factors; Tolvaptan; Young Adult	2020
Tolvaptan or transplant: why wait? Kidney international, 2020, Volume: 98, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability. Kidney international, 2020, Volume: 98, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan	2020
Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity. Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:2 Topics: Bile Acids and Salts; Biological Transport; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Hepatocytes; Humans; Liver; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2021
Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. American journal of nephrology, 2020, Volume: 51, Issue:9 Topics: Adult; Drug Resistance; Female; Genetic Testing; Glomerular Filtration Rate; Humans; Male; Middle Aged; Mutation; Polycystic Kidney, Autosomal Dominant; Retrospective Studies; Tolvaptan; TRPP Cation Channels	2020
Re: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. The Journal of urology, 2020, Volume: 204, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study. Current vascular pharmacology, 2021, Volume: 19, Issue:5 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Pilot Projects; Polycystic Kidney, Autosomal Dominant; Quality of Life; Tolvaptan; Treatment Outcome	2021
Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite. Toxicological sciences : an official journal of the Society of Toxicology, 2021, 01-06, Volume: 179, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Chemical and Drug Induced Liver Injury; Humans; Leukocytes, Mononuclear; Pharmaceutical Preparations; Polycystic Kidney, Autosomal Dominant; T-Lymphocytes; Tolvaptan	2021
Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations. Clinical and experimental nephrology, 2021, Volume: 25, Issue:3 Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Female; Genetic Predisposition to Disease; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Mutation; Polycystic Kidney, Autosomal Dominant; Recovery of Function; Retrospective Studies; Time Factors; Tolvaptan; Tomography, X-Ray Computed; Treatment Outcome; TRPP Cation Channels	2021
Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions. The journal of medical investigation : JMI, 2020, Volume: 67, Issue:3.4 Topics: Adult; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan. American journal of nephrology, 2020, Volume: 51, Issue:11 Topics: Adult; Aged; Body Height; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Patient Selection; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Reference Values; Retrospective Studies; Risk Assessment; ROC Curve; Severity of Illness Index; Time Factors; Tolvaptan	2020
[Autosomal dominant polycystic kidney disease : a pediatric perspective]. Revue medicale de Liege, 2020, Volume: 75, Issue:12 Topics: Adult; Animals; Child; Disease Progression; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand? Clinical journal of the American Society of Nephrology : CJASN, 2020, 12-31, Volume: 16, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Tolvaptan-induced remission of primary palmar hyperhidrosis in a patient with ADPKD: a serendipitous finding. Journal of nephrology, 2022, Volume: 35, Issue:2 Topics: Adolescent; Adult; Hand; Humans; Hyperhidrosis; Male; Polycystic Kidney, Autosomal Dominant; Sympathectomy; Tolvaptan; Treatment Outcome	2022
Short-term changes in micturition patterns with tolvaptan treatment for autosomal dominant polycystic kidney disease. Asian journal of surgery, 2021, Volume: 44, Issue:10 Topics: Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Urination	2021
Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study. Clinical and experimental nephrology, 2018, Volume: 22, Issue:3 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Creatinine; Female; Heart Failure; Humans; Male; Middle Aged; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan	2018
Tolvaptan and Autosomal Dominant Polycystic Kidney Disease. The New England journal of medicine, 2017, 11-16, Volume: 377, Issue:20 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2017
Tolvaptan in Later-Stage Polycystic Kidney Disease. The New England journal of medicine, 2018, 02-01, Volume: 378, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2018
REPRISE: tolvaptan in advanced polycystic kidney disease. Kidney international, 2018, Volume: 93, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2018
Tolvaptan in Later-Stage Polycystic Kidney Disease. The New England journal of medicine, 2018, 02-01, Volume: 378, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2018
Tolvaptan in Later-Stage Polycystic Kidney Disease. The New England journal of medicine, 2018, 02-01, Volume: 378, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2018
Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment. Clinical and experimental nephrology, 2018, Volume: 22, Issue:4 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Antigens, CD; Female; GPI-Linked Proteins; Humans; Kidney; Leukocytes, Mononuclear; Male; Mice; Middle Aged; Polycystic Kidney, Autosomal Dominant; Semaphorins; T-Lymphocytes, Regulatory; Tolvaptan	2018
Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD). Clinical and experimental nephrology, 2018, Volume: 22, Issue:5 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Child, Preschool; Female; Humans; Liver; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2018
A Clinical Patient Reporting Tool: Giving ADPKD Patients Back Their Data. Praxis, 2018, Volume: 107, Issue:8 Topics: Access to Information; Adult; Benzazepines; Cohort Studies; Databases, Factual; Decision Making; Health Literacy; Humans; Medical Records Systems, Computerized; Middle Aged; Patient Participation; Polycystic Kidney, Autosomal Dominant; Risk Assessment; Switzerland; Tolvaptan	2018
Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer? Clinical journal of the American Society of Nephrology : CJASN, 2018, 07-06, Volume: 13, Issue:7 Topics: Antidiuretic Hormone Receptor Antagonists; Clinical Trials, Phase III as Topic; Humans; Multicenter Studies as Topic; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2018
Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan. Clinical and experimental nephrology, 2018, Volume: 22, Issue:5 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Creatinine; Glomerular Filtration Rate; Humans; Middle Aged; Polycystic Kidney, Autosomal Dominant; Reproducibility of Results; Retrospective Studies; Tolvaptan	2018
[Practical approach to patient therapy affected by Autosomal Dominant Autosomic Polycystic Kidney Disease]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2018, Volume: 35, Issue:4 Topics: Antidiuretic Hormone Receptor Antagonists; Drug Interactions; Humans; Polycystic Kidney, Autosomal Dominant; Practice Guidelines as Topic; Tolvaptan	2018
Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models. Pediatric nephrology (Berlin, Germany), 2019, Volume: 34, Issue:10 Topics: Antidiuretic Hormone Receptor Antagonists; Calcium Signaling; Cell Line; Cell Proliferation; Cilia; Clinical Trials as Topic; Glucosidases; Humans; Kidney; Mutation; Polycystic Kidney, Autosomal Dominant; Primary Cell Culture; Tolvaptan; TOR Serine-Threonine Kinases; Treatment Outcome; TRPP Cation Channels	2019
Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 01-01, Volume: 34, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney, Autosomal Dominant; Prognosis; Tolvaptan	2019
Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 01-01, Volume: 34, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney, Autosomal Dominant; Prognosis; Tolvaptan	2019
Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression. American journal of nephrology, 2018, Volume: 48, Issue:4 Topics: Adult; Age Factors; Algorithms; Antidiuretic Hormone Receptor Antagonists; Clinical Decision-Making; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Patient Selection; Polycystic Kidney, Autosomal Dominant; Predictive Value of Tests; Retrospective Studies; Tolvaptan; Ultrasonography	2018
Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. Drug metabolism and disposition: the biological fate of chemicals, 2019, Volume: 47, Issue:2 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Hepatobiliary Elimination; Humans; In Vitro Techniques; Kidney; Liver; Male; Perfusion; Polycystic Kidney, Autosomal Dominant; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Cell Surface; Tolvaptan	2019
Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease. Journal of clinical pharmacology, 2019, Volume: 59, Issue:5 Topics: Adult; Clinical Trials as Topic; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Models, Biological; Polycystic Kidney, Autosomal Dominant; Reproducibility of Results; Tolvaptan	2019
Novel increasing dose regimen of tolvaptan for autosomal dominant polycystic kidney disease in patient with low tolerability. Nephrology (Carlton, Vic.), 2018, Volume: 23, Issue:8 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Polycystic Kidney, Autosomal Dominant; Polyuria; Tolvaptan; Treatment Outcome	2018
Clinical experience with tolvaptan in patients with polycystic kidney disease. Medicina clinica, 2020, 07-24, Volume: 155, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
What can copeptin tell us in patients with autosomal dominant polycystic disease? Kidney international, 2019, Volume: 96, Issue:1 Topics: Disease Progression; Glycopeptides; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Annals of internal medicine, 2013, Sep-17, Volume: 159, Issue:6 Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Benzazepines; Cost-Benefit Analysis; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Life Expectancy; Male; Markov Chains; Middle Aged; Polycystic Kidney, Autosomal Dominant; Quality-Adjusted Life Years; Tolvaptan	2013
Translating science to improve health: hope for patients with kidney disease at what cost? Annals of internal medicine, 2013, Sep-17, Volume: 159, Issue:6 Topics: Benzazepines; Female; Humans; Male; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2013
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:1 Topics: Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Line, Tumor; Cell Membrane; Cyclic AMP; Deamino Arginine Vasopressin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microsatellite Repeats; Models, Genetic; Polycystic Kidney, Autosomal Dominant; Somatostatin; Tolvaptan; TRPP Cation Channels	2015
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 65, Issue:6 Topics: Acute Kidney Injury; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Cohort Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glomerular Filtration Rate; Glycopeptides; Humans; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Tolvaptan; Treatment Outcome	2015
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug safety, 2015, Volume: 38, Issue:11 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chemical and Drug Induced Liver Injury; Databases, Factual; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Retrospective Studies; Statistics as Topic; Tolvaptan	2015
Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan. Clinical journal of the American Society of Nephrology : CJASN, 2015, Oct-07, Volume: 10, Issue:10 Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Case-Control Studies; EGF Family of Proteins; Epidermal Growth Factor; Female; Glomerular Filtration Rate; Heparin-binding EGF-like Growth Factor; Humans; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Polycystic Kidney, Autosomal Dominant; Severity of Illness Index; Tolvaptan; Transforming Growth Factor alpha	2015
Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury? Toxicological sciences : an official journal of the Society of Toxicology, 2016, Volume: 149, Issue:1 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Carrier Proteins; Chemical and Drug Induced Liver Injury; CHO Cells; Cricetulus; Hepatocytes; Humans; Membrane Glycoproteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polycystic Kidney, Autosomal Dominant; Taurocholic Acid; Tolvaptan	2016
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, Jun-01, Volume: 32, Issue:6 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Chemokine CCL2; Creatinine; Female; Humans; Kidney; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2017
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. Pediatric nephrology (Berlin, Germany), 2017, Volume: 32, Issue:5 Topics: Benzazepines; Edema; Female; Glomerular Filtration Rate; Humans; Infant, Newborn; Kidney Function Tests; Parenteral Nutrition; Polycystic Kidney, Autosomal Dominant; Pregnancy; Receptors, Vasopressin; Tolvaptan; Treatment Outcome; TRPP Cation Channels; Young Adult	2017
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:5 Topics: Adult; Aged; Amiloride; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blotting, Western; Cell Proliferation; Cells, Cultured; Chlorides; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; Diuretics; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Renal Agents; Tolvaptan; Vasopressins	2011
Aquaretic treatment in polycystic kidney disease. The New England journal of medicine, 2012, Dec-20, Volume: 367, Issue:25 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Kidney; Male; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2012
V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:4 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Kidney Diseases, Cystic; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive; Tolvaptan	2005
Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrology news & issues, 2008, Volume: 22, Issue:3 Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Child; Clinical Trials as Topic; Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Octreotide; Polycystic Kidney, Autosomal Dominant; Protein Kinases; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases	2008